BARCELONA, Spain–(BUSINESS WIRE)–Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its results for the first nine months of 2026. Net Sales rose 8.3% YoY to €889.2 MM and EBITDA grew 22.7% to €221.7 MM, representing a margin of 24.9%. With steady performance in line with its long-term growth trajectory, Almirall reiterated its full-year 2026 guidance. The European Dermatology business remained the main engine of Almirall’s growth, with Net
